Cargando…
Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19–Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021
IMPORTANCE: COVID-19 vaccine might be less immunogenic and effective among residents of long-term care facilities (LTCFs). OBJECTIVE: To examine the association of BNT162b2 third dose (first booster dose) with overall SARS-CoV-2 infection, COVID-19 hospitalizations, and mortality among LTCF resident...
Autores principales: | Muhsen, Khitam, Maimon, Nimrod, Mizrahi, Amiel Yaron, Varticovschi, Baruch, Bodenheimer, Omri, Cohen, Dani, Dagan, Ron |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Medical Association
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9250055/ https://www.ncbi.nlm.nih.gov/pubmed/35796153 http://dx.doi.org/10.1001/jamanetworkopen.2022.19940 |
Ejemplares similares
-
Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel
por: Muhsen, Khitam, et al.
Publicado: (2021) -
Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2021) -
Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization
por: Chodick, Gabriel, et al.
Publicado: (2021) -
Waning Immunity after the BNT162b2 Vaccine in Israel
por: Goldberg, Yair, et al.
Publicado: (2021) -
Protection by a Fourth Dose of BNT162b2 against Omicron in Israel
por: Bar-On, Yinon M., et al.
Publicado: (2022)